CN1505512A - 包含托塞米变型ⅱ的稳定药物制剂 - Google Patents

包含托塞米变型ⅱ的稳定药物制剂 Download PDF

Info

Publication number
CN1505512A
CN1505512A CNA018231683A CN01823168A CN1505512A CN 1505512 A CN1505512 A CN 1505512A CN A018231683 A CNA018231683 A CN A018231683A CN 01823168 A CN01823168 A CN 01823168A CN 1505512 A CN1505512 A CN 1505512A
Authority
CN
China
Prior art keywords
torsemide modification
pharmaceutical preparation
modification
torsemide
stabilised pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018231683A
Other languages
English (en)
Chinese (zh)
Inventor
Mά
M·莱伯维茨
۸���
R·特嫩高泽
M·科佩尔
˹��ϣķ
J·阿伦希姆
M·科尔多瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27359046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1505512(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN1505512A publication Critical patent/CN1505512A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA018231683A 2000-02-17 2001-02-21 包含托塞米变型ⅱ的稳定药物制剂 Pending CN1505512A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18328800P 2000-02-17 2000-02-17
US09/789,424 US6482417B2 (en) 2000-02-17 2001-02-21 Stable pharmaceutical formulation comprising torsemide modification II
PCT/US2001/005577 WO2002067935A1 (en) 2000-02-17 2001-02-21 A stable pharmaceutical formulation comprising torsemide modification ii

Publications (1)

Publication Number Publication Date
CN1505512A true CN1505512A (zh) 2004-06-16

Family

ID=27359046

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018231683A Pending CN1505512A (zh) 2000-02-17 2001-02-21 包含托塞米变型ⅱ的稳定药物制剂

Country Status (20)

Country Link
US (1) US6482417B2 (enExample)
EP (1) EP1292303B1 (enExample)
JP (1) JP2004522780A (enExample)
CN (1) CN1505512A (enExample)
AT (1) ATE266404T1 (enExample)
CA (1) CA2410802A1 (enExample)
DE (2) DE1292303T1 (enExample)
DK (1) DK1292303T3 (enExample)
ES (1) ES2193007T3 (enExample)
HR (1) HRP20030762A2 (enExample)
HU (1) HUP0600143A2 (enExample)
IL (1) IL157539A0 (enExample)
IS (1) IS6919A (enExample)
MX (1) MXPA03007908A (enExample)
NO (1) NO20033699L (enExample)
PT (1) PT1292303E (enExample)
SI (1) SI1292303T1 (enExample)
SK (1) SK11632003A3 (enExample)
TR (1) TR200401462T4 (enExample)
WO (1) WO2002067935A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100372534C (zh) * 2006-04-20 2008-03-05 南京海辰药业有限公司 托拉塞米冻干制剂及制备方法
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN1946379B (zh) * 2004-03-25 2012-05-16 菲尔若国际公司 含有托拉塞米和基质成型聚合物的延长释放组合物
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
WO2005044187A2 (en) * 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
US20080213362A1 (en) * 2007-02-02 2008-09-04 Lawrence Solomon Compositions and methods using torsemide
GR1010905B (el) * 2024-04-15 2025-03-10 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Δισκιο που περιεχει τορασεμιδη

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
CA2213700C (en) * 1995-02-28 2002-04-02 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
HRP20020120A2 (en) * 1999-08-11 2003-10-31 Teva Pharma Torsemide polymorphs

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946379B (zh) * 2004-03-25 2012-05-16 菲尔若国际公司 含有托拉塞米和基质成型聚合物的延长释放组合物
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN100372534C (zh) * 2006-04-20 2008-03-05 南京海辰药业有限公司 托拉塞米冻干制剂及制备方法
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片

Also Published As

Publication number Publication date
JP2004522780A (ja) 2004-07-29
DK1292303T3 (da) 2004-09-06
EP1292303A4 (en) 2003-07-09
IS6919A (is) 2003-08-20
DE60103276T2 (de) 2005-06-23
SK11632003A3 (sk) 2004-04-06
SI1292303T1 (en) 2004-10-31
MXPA03007908A (es) 2004-12-06
TR200401462T4 (tr) 2004-08-23
EP1292303A1 (en) 2003-03-19
CA2410802A1 (en) 2002-09-06
HUP0600143A2 (en) 2006-10-28
HRP20030762A2 (en) 2005-08-31
ES2193007T3 (es) 2004-11-01
IL157539A0 (en) 2004-03-28
US6482417B2 (en) 2002-11-19
US20020035135A1 (en) 2002-03-21
WO2002067935A1 (en) 2002-09-06
ES2193007T1 (es) 2003-11-01
DE60103276D1 (de) 2004-06-17
DE1292303T1 (de) 2003-09-18
NO20033699L (no) 2003-10-10
EP1292303B1 (en) 2004-05-12
NO20033699D0 (no) 2003-08-20
ATE266404T1 (de) 2004-05-15
PT1292303E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
CN1129598C (zh) 具有改进溶解性的伊曲康唑、其制备方法和含有伊曲康唑的口服药物组合物
CN1124130C (zh) 含氯甲双磷酸盐活性成分和硅化微晶纤维素赋形剂的药物制剂
HK1046277A1 (en) Benzamide formulation with histone deacetylase inhibitor activity
CN1360499A (zh) 含有非诺贝特的药物组合物及其制备方法
JP2010534211A (ja) ジヒドロピリジンカルシウムチャンネルアンタゴニストを含む薬学的組成物とその調製方法
JP2002513760A (ja) パロキセチン固体分散体を製造するための水系方法
CA2662265A1 (en) Imatinib compositions
CN1505512A (zh) 包含托塞米变型ⅱ的稳定药物制剂
KR20220060488A (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정성 입자의 제조방법 및 이를 포함하는 약학적 조성물
CN1133431C (zh) 用罗西格列酮和胰岛素治疗糖尿病
CN1112926C (zh) 含有5－[4－[2－(n－甲基－n－2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的组合物
CN1240377C (zh) 普伐他汀的稳定的药物组合物
JP2003517432A (ja) プラバスタチンナトリウム含有薬剤組成物
JP6179515B2 (ja) 安定化された内服用固形製剤
JP2022112698A (ja) アピキサバン含有医薬組成物
US20030022921A1 (en) Stable pharmaceutical formulation comprising torsemide modification II
JP2020183382A (ja) フィンゴリモド塩酸塩含有製剤及びフィンゴリモド塩酸塩含有製剤の製造方法
AU2001238617A1 (en) A stable pharmaceutical formulation comprising torsemide modification II
KR20030077638A (ko) 토르세마이드 변형체 ⅱ를 포함하는 안정한 약학 제제
KR20190007370A (ko) 바제독시펜 또는 그의 약제학적으로 허용가능한 염, 및 콜레칼시페롤 또는 그의 약제학적으로 허용가능한 염을 포함하는 우수한 안정성 및 용출률을 갖는 복합제제
WO2025166343A1 (en) Tablet formulation of tafamidis or pharmaceutically acceptable salt thereof
WO2012062691A1 (en) Pharmaceutical compositions for treating hcv infections
ZA200306679B (en) A stable pharmaceutical formulation comprising torsemide modification II.
CZ20032513A3 (cs) Stabilní farmaceutický přípravek obsahující modifikaci II torsemidu
CN1695739A (zh) 含有难溶解性主药之持续释放配方

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication